ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aldeyra Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.67−0.03 (-5.00%)
Close on Oct 19, 2026
- Market cap
- $40.12M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$4.5949 (−87.36%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $40.12M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.06
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$23.05M
- EPS, diluted
- -$0.39
- Book value per share
- $0.63
- Diluted shares
- 60M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Operating income
-$24.07M
Net income
-$23.05M
EPS, diluted
-$0.39
Free cash flow
–
Reported periodTrailing twelve months